Related references
Note: Only part of the references are listed.The value of biomarkers in bone metastasis
Stella D'Oronzo et al.
EUROPEAN JOURNAL OF CANCER CARE (2017)
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
Hiroji Uemura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
James L. Gulley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
Justin Guinney et al.
LANCET ONCOLOGY (2017)
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet
Daniel P. Petrylak et al.
TARGETED ONCOLOGY (2017)
Navigating the evolving therapeutic landscape in advanced prostate cancer
E. David Crawford et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer
Kai H. Hammerich et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
James L. Gulley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy
Mehmet Asim Bilen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen et al.
CLINICAL CANCER RESEARCH (2017)
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223
O. Sartor et al.
ANNALS OF ONCOLOGY (2017)
Evaluation of bone metastases by 18F-choline PET/CT in a patient with castration-resistant prostate cancer treated with radium-223
Piera Scalzi et al.
UROLOGIA JOURNAL (2017)
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
K. N. Chi et al.
ANNALS OF ONCOLOGY (2016)
Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer
Jack Schalken et al.
BJU INTERNATIONAL (2016)
Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis
Diane S. Abou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Whole-Body and Microenvironmental Localization of Radium-223 in Naive and Mouse Models of Prostate Cancer Metastasis
Diane S. Abou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
Phillip Mikah et al.
BMC CANCER (2016)
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
Begona Mellado et al.
CLINICAL GENITOURINARY CANCER (2016)
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
Fred Saad et al.
LANCET ONCOLOGY (2016)
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
Samanta Salvi et al.
ONCOTARGET (2016)
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study
Elena Verzoni et al.
ONCOTARGET (2016)
Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigenspecific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
Anthony S. Malamas et al.
ONCOTARGET (2016)
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
Shimpei Yamashita et al.
BMC UROLOGY (2016)
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
Peter F. Mulders et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC)
Martin Boegemann et al.
CURRENT CANCER DRUG TARGETS (2015)
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
R. J. van Soest et al.
EUROPEAN JOURNAL OF CANCER (2015)
Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer
Karim Fizazi et al.
EUROPEAN UROLOGY (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
Michele Iuliani et al.
ONCOTARGET (2015)
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
Daniel J. George et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer
Kyle S. Miyazaki et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer
John M. Fitzpatrick et al.
EUROPEAN UROLOGY (2014)
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)
Dana E. Rathkopf et al.
EUROPEAN UROLOGY (2014)
Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer
Hideyasu Matsuyama et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Serum alkaline phosphatase differentiates prostate-specific antigen flare from early disease progression after docetaxel chemotherapy in castration-resistant prostate cancer with bone metastasis
Kyung Seok Han et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421
Primo N. Lara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial
Oliver Sartor et al.
LANCET ONCOLOGY (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer
Adam R. Metwalli et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
Abiraterone in the treatment of metastatic castration-resistant prostate cancer
Elahe A. Mostaghel
CANCER MANAGEMENT AND RESEARCH (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
A. Bahl et al.
ANNALS OF ONCOLOGY (2013)
Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer
Rhonda L. Bitting et al.
CANCER JOURNAL (2013)
Castrate-resistant prostate cancer: postdocetaxel management
Song Zhao et al.
CURRENT OPINION IN UROLOGY (2013)
Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis
Mari I. Suominen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
Susan Halabi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
David I. Quinn et al.
LANCET ONCOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
S. Nilsson et al.
EUROPEAN JOURNAL OF CANCER (2012)
Prostate Cancer Cells and Bone Stromal Cells Mutually Interact with Each Other through Bone Morphogenetic Protein-mediated Signals
Hikaru Nishimori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J. Logothetis et al.
LANCET ONCOLOGY (2012)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy
Guru Sonpavde et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
Yasser Rehman et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Human Prostate Cancer Harbors the Stem Cell Properties of Bone Marrow Mesenchymal Stem Cells
Haiyen E. Zhau et al.
CLINICAL CANCER RESEARCH (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
F-18-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with Ra-223-chloride (Alpharadin)
Gary J. R. Cook et al.
EJNMMI RESEARCH (2011)
Cancer to bone: a fatal attraction
Katherine N. Weilbaecher et al.
NATURE REVIEWS CANCER (2011)
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Meng-Lei Zhu et al.
CANCER RESEARCH (2010)
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
Cabazitaxel
Matthew D. Galsky et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evolving Role of Bone Biomarkers in Castration-Resistant Prostate Cancer
Janet E. Brown et al.
NEOPLASIA (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
Tissue-nonspecific Alkaline Phosphatase Is Required for the Calcification of Collagen in Serum A POSSIBLE MECHANISM FOR BIOMINERALIZATION
Paul A. Price et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Docetaxel Down-Regulates the Expression of Androgen Receptor and Prostate-Specific Antigen But Not Prostate-Specific Membrane Antigen in Prostate Cancer Cell Lines: Implications for PSA Surrogacy
Kenji Kuroda et al.
PROSTATE (2009)
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran et al.
SCIENCE (2009)
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2007)
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer:: a randomised, multicentre, placebo-controlled phase II study
Sten Nilsson et al.
LANCET ONCOLOGY (2007)
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
Theresa A. Guise et al.
CLINICAL CANCER RESEARCH (2006)
High-linear energy transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra:: Adjuvant or alternative to conventional modalities?
Oyvind S. Bruland et al.
CLINICAL CANCER RESEARCH (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer
Richard J. Cook et al.
CLINICAL CANCER RESEARCH (2006)
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
RE Coleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases
S Nilsson et al.
CLINICAL CANCER RESEARCH (2005)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
JE Brown et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines
M Zayzafoon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry
K Knerr et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro
DL Lin et al.
PROSTATE (2001)
Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients
L Bubendorf et al.
HUMAN PATHOLOGY (2000)
Share Paper
